Notice of NHLBI Participation in NOT-AT-21-002 "Notice of Special Interest (NOSI): Promoting Research on Interoception and Its Impact on Health and Disease (R01)”
Notice Number:
NOT-HL-21-037

Key Dates

Release Date:

October 26, 2021

Related Announcements

NOT-AT-21-002 - Notice of Special Interest (NOSI): Promoting Research on Interoception and Its Impact on Health and Disease

PA-20-183 - Research Project Grant (Parent R01 Clinical Trial Required)

PA-20-185 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)

Issued by

National Heart, Lung, and Blood Institute (NHLBI)

Purpose

The purpose of this Notice is to inform potential applicants that the National Heart, Lung, and Blood Institute (NHLBI) is participating, effective immediately, in NOT-AT-21-002 "Notice of Special Interest (NOSI): Promoting Research on Interoception and Its Impact on Health and Disease".

Research Objectives

For this NOSI, NHLBI is interested in basic, translational, and clinical research to examine interoceptive processes and mechanisms mediating heart, lung, blood, and sleep (HLBS) normal biological function, resilience, and disease pathophysiology.

Research Examples

Topics of interest include, but are not limited to:

  • Changes in interoceptive processes that might lead to alterations in HLBS function under normal conditions at the cell, tissue, and systemic levels.
  • Disruptions in interoceptive processes that might lead to or exacerbate the development, progression, and manifestations of arrhythmias, heart failure, hypo- and hypertension, postural orthostatic tachycardia syndrome, dyspnea, chronic cough, sleep and circadian rhythms disorders, and sickle cell disease pain.
  • Impact on interoceptive systems by HLBS disease-related structural and functional remodeling in cardiopulmonary neural circuits.
  • Computational integrative approaches elucidating autonomic nervous system pathophysiology and modeling neuromodulation-based personalized therapies for HLBS diseases.
  • Effects of changes in sympathetic and parasympathetic tone in heart failure on other organs or alterations neuroendocrine signaling in other tissues.
  • Elucidation of sleep-related interoceptive processes (e.g., the perception of sleep quality, sleepiness, and fatigue).
  • Investigation of how disruptions in interoceptive processes might lead to, accelerate, or exacerbate vascular contributions to cognitive impairment and dementia, and vice versa, how cognitive deficiencies associated with vascular diseases might impact interoceptive systems.
  • Research on microbiota dysbiosis in the lungs and gut and how its effects on hypersensitivity and altered pain perception could be explored in therapeutic interventions.
  • Identify acute vs. chronic effects of abnormal respiratory interoception in lung disorders.
  • Development of clinically relevant protocols for manipulating respiratory interoception for disease intervention.
  • Establishment of pre-clinical models for assessment of pulmonary neuroimmunoregulation, microbiomes, and development of interventional targets.
  • Identification of cardiovascular and respiratory interoceptive markers with diagnostic and prognostic value.
  • Research on blood immune cell interactions with heart and lungs.
  • Interaction of peripheral and central nervous systems with bone marrow cells to regulate hematopoietic system function during development, homeostasis, psychosocial stress, and hematopoietic stem cell transplantation.
  • Interoceptive mechanisms regulating acute vs. chronic sickle cell disease pain.
  • Development and testing of interventions to increase interoceptive awareness of hunger/satiety in patients with obesity and symptom perception in patients with cardiovascular conditions.

Note: For this NOSI, NHLBI will only accept applications that target PA-20-185 NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) and PA-20-183 NIH Research Project Grant (Parent R01 Clinical Trial Required).

For PA-20-183 NIH Research Project Grant (Parent R01 Clinical Trial Required), NHLBI only accepts mechanistic studies that meet NIH's definition of a clinical trial.

Inquiries

Please direct all inquiries to:

Scientific/Research Contact

Olga Tjurmina, Ph.D.
National Heart, Lung, and Blood Institute
Division of Cardiovascular Sciences
Telephone: 301-435-0504
Email: olga.tjurmina@nih.gov

Financial/Grants Management Contact

Diane Zwinak
Telephone: 301-402-5233
Email: diane.zwinak@nih.gov


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices